
Galapagos is a midsized biotechnology company, with therapeutic programs based on proprietary disease modifying drug targets, and a focus on inflammation, orphan disease, and anti-infectives. Galapagos' approach is to develop drugs that stop or reverse a disease state using novel targets that are id... Galapagos is a midsized biotechnology company, with therapeutic programs based on proprietary disease modifying drug targets, and a focus on inflammation, orphan disease, and anti-infectives. Galapagos' approach is to develop drugs that stop or reverse a disease state using novel targets that are identified through a patent protected target discovery platform. Galapagos also provides access to its target and drug discovery platform through its services division, BioFocus and Argenta, which offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies. Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | -3.8977 | -14.4846372244 | 26.9092 | 26.9092 | 23.0115 | 161 | 25.63199789 | CS |
26 | -1.5385 | -6.26680244399 | 24.55 | 26.9092 | 23.0115 | 108 | 25.61821769 | CS |
52 | -3.1885 | -12.1698473282 | 26.2 | 26.9092 | 22.6 | 71 | 25.6857421 | CS |
156 | -40.9885 | -64.04453125 | 64 | 64 | 22.6 | 9879 | 41.05686215 | CS |
260 | -130.2385 | -84.9843393148 | 153.25 | 223 | 22.6 | 5027 | 67.25325516 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales